MetaVia Gets IRB Approval for Phase 1 Part 3 Trial of DA-1726 Obesity Drug

MetaVia, a US biotech subsidiary of South Korea's Dong-A ST, has received IRB approval to begin testing high doses of its experimental obesity treatment, DA-1726. The Phase 1 Part 3 clinical trial will evaluate the safety and tolerability of the drug in 40 healthy volunteers. The trial is expected to begin in April, with top-line data planned for Q4 2026. DA-1726 targets both GLP-1 and glucagon receptors to suppress appetite and increase metabolic rate, demonstrating promising efficacy in a previous Phase 1 study.